Topical application of senolytic ABT-263 accelerates wound healing in aged mice
Researchers at Boston University found that applying the senolytic drug ABT-263 directly to the skin of aged mice reduced the accumulation of senescent cells and significantly improved wound healing rates. The study suggests that clearing damaged cells before an injury occurs may prime aging skin for a more robust repair response, potentially offering a future strategy for managing slow-healing wounds in older adults.
Key points
- A study published in Aging-US found that topical application of ABT-263 to aged mice reduced senescent cells and improved wound healing outcomes.
- By day 24, 80% of treated mice had fully healed wounds, compared to only 56% of untreated aged mice.
- The treatment temporarily increased inflammatory activity, which appeared to activate repair machinery and boost genes involved in collagen production and blood vessel formation.
- ABT-263 selectively targeted senescent cells in aged skin without producing the same effect in young mice, likely due to the higher concentration of damaged cells in older tissues.
- The researchers propose that pre-treating skin with senolytics could serve as a strategy for preoperative care to enhance recovery in older patients.
Background
This research builds on recent interest in senolytic therapies, such as the experimental drug rentosertib, which has shown potential in reversing biological aging markers in lung disease trials. While previous studies focused on systemic aging clocks, this new work highlights the specific benefits of targeting senescent cells in skin tissue to improve functional outcomes like wound repair. It also aligns with broader discussions about the need for functional gains, not just biomarker changes, to define true aging reversal.
Why it matters
Slow-healing wounds are a significant challenge for older adults, often leading to complications from surgery or chronic health issues. If topical senolytics can safely accelerate healing in humans, they could reduce recovery times and improve quality of life for aging populations. The localized application method may also minimize systemic side effects associated with oral senolytic drugs.
What to watch
The next step is to determine whether the benefits observed in mice translate to humans. Researchers must conduct clinical trials to assess the safety and effectiveness of topical ABT-263 in people. If successful, this approach could be integrated into preoperative care protocols for older patients to optimize surgical recovery.
Want the full story? Read the original reporting
Read on ScienceDaily